Kastinen, Meeri
Sirniö, Päivi
Elomaa, Hanna
Ahtiainen, Maarit
Väyrynen, Sara A.
Herzig, Karl-Heinz
Meriläinen, Sanna
Aro, Raila
Häivälä, Reetta
Rautio, Tero
Saarnio, Juha
Wirta, Erkki-Ville http://orcid.org/0000-0002-2255-6136
Helminen, Olli
Seppälä, Toni T.
Kuopio, Teijo
Böhm, Jan
Tuomisto, Anne http://orcid.org/0000-0002-9949-1887
Mecklin, Jukka-Pekka
Mäkinen, Markus J. http://orcid.org/0000-0002-9200-4118
Väyrynen, Juha P. http://orcid.org/0000-0002-8683-2996
Funding for this research was provided by:
Syöpäsäätiö (59-5619)
Article History
Received: 3 November 2022
Revised: 21 March 2023
Accepted: 23 March 2023
First Online: 8 April 2023
Competing interests
: TTS is the CEO and co-owner of Healthfund Finland Oy, and reports interview honoraria from Boehringer Ingelheim Finland and Amgen Finland.
: The study was conducted according to the guidelines of the Declaration of Helsinki. The use of Cohort 1 was approved by the hospital administration and the ethics board (Dnro13U/2011, 1/2016 and 8/2020) and the National Supervisory Authority for Welfare and Health (Valvira). The need to obtain informed consent from the study patients was waived (Valvira Dnro 3916/06.01.03.01/2016). The studies involving Cohorts 2 and 3 were conducted under permission form the Ethical Committee of the North Ostrobothnia’s Hospital District (25/2002, 42/2005, 122/2009, 37/2020), Biobank Borealis (BB-2017_1012) and Fimea (FIMEA72022/001941).
: Not applicable.